Literature DB >> 14693423

GLP-1 inhibition of pancreatic islet cell apoptosis.

Irina A Urusova1, Loredana Farilla, Hongxiang Hui, Eugenio D'Amico, Riccardo Perfetti.   

Abstract

Apoptosis plays an important role in the normal physiology of the pancreas, the pathogenesis of diabetes mellitus (DM) and the success rate of islet transplantation. Glucagon-like peptide-1 (GLP-1), an incretin hormone with multiple effects on glucose metabolism and pancreatic gene expression, has recently been found to have antiapoptotic properties. This new property of GLP-1 has clinical relevance for the treatment of patients with overt DM, possible prevention of DM during the stage of impaired glucose tolerance and improvement in the outcome of islet transplantation. The pleiotropic effects of GLP-1 have fostered considerable interest in evaluating the efficacy of GLP-1, and might lead in the near future to its use in the prevention and/or treatment of DM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693423     DOI: 10.1016/j.tem.2003.11.006

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  18 in total

Review 1.  Development of the endocrine pancreas.

Authors:  David J Hill
Journal:  Rev Endocr Metab Disord       Date:  2005-08       Impact factor: 6.514

Review 2.  Nanotechnology in cell replacement therapies for type 1 diabetes.

Authors:  Alexander U Ernst; Daniel T Bowers; Long-Hai Wang; Kaavian Shariati; Mitchell D Plesser; Natalie K Brown; Tigran Mehrabyan; Minglin Ma
Journal:  Adv Drug Deliv Rev       Date:  2019-02-02       Impact factor: 15.470

3.  Effects of glucagon-like peptide 1 on glycemia control and its metabolic consequence after severe thermal injury--studies in an animal model.

Authors:  Chuan-an Shen; Shawn Fagan; Alan J Fischman; Edward E Carter; Jia-Ke Chai; Xiao-Ming Lu; Yong-Ming Yu; Ronald G Tompkins
Journal:  Surgery       Date:  2011-02-05       Impact factor: 3.982

4.  Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes.

Authors:  A Sharma; A Sörenby; A Wernerson; S Efendic; M Kumagai-Braesch; A Tibell
Journal:  Diabetologia       Date:  2006-04-12       Impact factor: 10.122

5.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

Review 6.  Glucagon-like peptide 1 based therapy for type 2 diabetes.

Authors:  Bao-Sheng Yu; An-Ru Wang
Journal:  World J Pediatr       Date:  2008-02       Impact factor: 2.764

Review 7.  GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects.

Authors:  Melanie Sulistio; Curtis Carothers; Mandeep Mangat; Mike Lujan; Rene Oliveros; Robert Chilton
Journal:  Curr Atheroscler Rep       Date:  2009-03       Impact factor: 5.113

Review 8.  Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation.

Authors:  Han Xie; Natesh Yepuri; Qinghe Meng; Ravi Dhawan; Colin A Leech; Oleg G Chepurny; George G Holz; Robert N Cooney
Journal:  Rev Endocr Metab Disord       Date:  2020-08-26       Impact factor: 6.514

9.  Exendin-4 attenuates neuronal death via GLP-1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats.

Authors:  Zhiyi Xie; Budbazar Enkhjargal; Lingyun Wu; Keren Zhou; Chengmei Sun; Xin Hu; Vadim Gospodarev; Jiping Tang; Chao You; John H Zhang
Journal:  Neuropharmacology       Date:  2017-10-04       Impact factor: 5.250

10.  Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes.

Authors:  J Zhang; Y Tokui; K Yamagata; J Kozawa; K Sayama; H Iwahashi; K Okita; M Miuchi; H Konya; T Hamaguchi; M Namba; I Shimomura; J-I Miyagawa
Journal:  Diabetologia       Date:  2007-07-14       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.